Resultados da pesquisa - Philip S Helliwell

Refinar resultados
  1. 1
    Assessing Disease Activity in Psoriatic Arthritis: A Literature Review

    Assessing Disease Activity in Psoriatic Arthritis: A Literature Review Por Laura J. Tucker, Laura C. Coates, Philip S. Helliwell

    Publicado em 2018-11-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians

    The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians Por Victoria Furer, Mitsumasa Kishimoto, Shigeyoshi Tsuji, Yoshinori Taniguchi, Yoko Ishihara, Tetsuya Tomita, Philip S. Helliwell, Ori Elkayam

    Publicado em 2020-09-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes

    Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes Por Iain B McInnes, Philip S Helliwell, Laura M Sawyer, Corinne LeReun, Kristen Markus, Celia Sabry-Grant

    Publicado em 2022-03-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies

    Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies Por Ana-Maria Orbai, Philip J. Mease, Philip S. Helliwell, Oliver FitzGerald, Dona L. Fleishaker, Rajiv Mundayat, Pamela Young

    Publicado em 2022-09-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials

    Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, r... Por Arthur Kavanaugh, Lianne S Gensler, Philip S Helliwell, Kristen Sweet, Yin You, Soumya D Chakravarty, Shelly Kafka, Chetan S Karyekar, Kim Campbell

    Publicado em 2020-02-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies

    Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies Por Philip J. Mease, Ana-Maria Orbai, Oliver FitzGerald, Mohamed Bedaiwi, Dona L. Fleishaker, Rajiv Mundayat, Pamela Young, Philip S. Helliwell

    Publicado em 2023-08-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Plantar plate pathology is associated with erosive disease in the painful forefoot of patients with rheumatoid arthritis

    Plantar plate pathology is associated with erosive disease in the painful forefoot of patients with rheumatoid arthritis Por Heidi J Siddle, Richard J Hodgson, Elizabeth M A Hensor, Andrew J Grainger, Anthony C Redmond, Richard J Wakefield, Philip S Helliwell

    Publicado em 2017-07-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

    Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo Por Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell

    Publicado em 2022-02-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

    Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity Por Laura C. Coates, Ana-Maria Orbai, Akimichi Morita, Olivier Benichou, Lisa Kerr, David H. Adams, Catherine L. Shuler, Julie Birt, Philip S. Helliwell

    Publicado em 2018-08-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib

    Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib Por Laura C. Coates, Andrew G. Bushmakin, Oliver FitzGerald, Dafna D. Gladman, Lara Fallon, Joseph C. Cappelleri, Ming-Ann Hsu, Philip S. Helliwell

    Publicado em 2021-03-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register

    The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register Por Gareth T. Jones, Gary J. Macfarlane, Karen Forrest Keenan, Paul McNamee, Aileen R. Neilson, Stefan Siebert, A. David Burden, Lesley Kay, Philip S. Helliwell

    Publicado em 2021-05-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis

    Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis Por Daniela Graham, Philip S Helliwell, Christopher Ritchlin, Alexis Ogdie, Jon T Giles, Rebecca Germino, Lori Stockert, Pamela Young, Wael Joseph, Rajiv Mundayat, Juan J Gómez-Reino

    Publicado em 2021-04-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

    Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis Por Josef S Smolen, Laura C Coates, Eric Lespessailles, Mitsumasa Kishimoto, Rebecca Bolce, Andrew J Bradley, M. Elaine Husni, Joseph F. Merola, Lisa Macpherson, Philip S. Helliwell

    Publicado em 2022-11-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

    Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis... Por Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell

    Publicado em 2023-03-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study Por Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff

    Publicado em 2024-02-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial

    Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial Por Atul Deodhar, Arthur Kavanaugh, Dafna D Gladman, Laura C Coates, Vibeke Strand, Philip S Helliwell, Alexis Ogdie, Lyrica X H Liu, Gregory Kricorian, David Collier, Phillip J Mease

    Publicado em 2022-07-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Elevating the Standard of Care for Patients with Psoriatic Arthritis: ‘Calls to Action’ from a Multistakeholder Pan-European Initiative

    Elevating the Standard of Care for Patients with Psoriatic Arthritis: ‘Calls to Action’ from a Multistakeholder Pan-European Initiative Por Iris Verbinnen, Emilio Monte-Boquet, Detlev Parow, Fabienne Lacombe, Andrew Pothecary, Arno W. R. van Kuijk, Laura Harrington, Edita Müllerová, Andreas Pinter, Ulrike Erstling, Andrea Tomasini, Philip S. Helliwell

    Publicado em 2024-04-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)

    Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinica... Por Michelle L. M. Mulder, Johanna E. Vriezekolk, Nathan den Broeder, Elien A. M. Mahler, Philip S. Helliwell, Frank H. J. van den Hoogen, Alfons A. den Broeder, Mark H. Wenink

    Publicado em 2020-02-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

    Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with ac... Por Proton Rahman, Philip J. Mease, Philip S. Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P. Kollmeier, Elizabeth C. Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S. Karyekar, Chenglong Han

    Publicado em 2021-07-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

    Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, plac... Por Peter Nash, Atul Deodhar, Philip J Mease, Dafna D Gladman, Philip S Helliwell, Dennis G McGonagle, Alice Gottlieb, Elizabeth C Hsia, Chetan S Karyekar, Wolf-Henning Boehncke, Xie L Xu, Stephen Xu

    Publicado em 2020-09-01
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: